Skip to main content Accessibility help
×
×
Home
  • Print publication year: 2014
  • Online publication date: October 2014

Chapter 28 - Antidepressants

from Section 4 - Treatment
Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

A Concise Guide to Understanding Suicide
  • Online ISBN: 9781139519502
  • Book DOI: https://doi.org/10.1017/CBO9781139519502
Please enter your name
Please enter a valid email address
Who would you like to send this to *
×

References

Acharya, N., Rosen, A., Polzer, J., et al (2006). Duloxetine: Meta-analysis of suicidal behaviors and ideation in clinical trials for major depressive disorder. Journal of Clinical Psychopharmacology, 26, 587–594.
Beasley, C., Dornseif, B., Bosomworth, J., et al (1991). Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ, 303, 685–692.
Borys, D. J., Setzer, S. C., Ling, L. J., et al. (1992). Acute fluoxetine overdose: a report of 234 cases. American Journal of Emergency Medicine, 10, 115–120.
Bridge, J. A., Iyengar, S., Salary, C. B., et al. (2007). Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA, 297, 1683–1696.
Buckley, N. A., & McManus, P. R. (2002). Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ, 325, 1332–1333.
Carpenter, D. J., Fong, R., Kraus, J. E., et al (2011). Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a completed set of randomized, placebo-controlled trials. Journal of Clinical Psychiatry, 72(11), 1503–1514.
Centers for Disease Control and Prevention. (2007). Suicide trends among youths and young adults aged 10–24 – United States, 1990–2004. Morbidity and Mortality Weekly Report, 56, 905–908
Emslie, G. J., Findling, R. L., & Yeung, P. P. (2007). Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 479–488.
Friedman, R., & Leon, A. (2007). Expanding the black box: depression, antidepressants, and the risk of suicide. New England Journal of Medicine, 356(23), 2343–2346.
Gibbons, R., Hur, K., Bhaumik, D. K., et al. (2005). The relationship between antidepressant medication use and rate of suicide. Archives of General Psychiatry, 62, 165–172.
Gibbons, R., Brown, C. H., Hur, K., et al. (2007a). Relationship between antidepressants and suicide attempts: an analysis of the veterans’ health administration data sets. American Journal of Psychiatry, 164, 1044–1049.
Gibbons, R. D., Brown, C. H., Hur, K., et al. (2007b). Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. American Journal of Psychiatry, 164(9), 1356–1363.
Gibbons, R. D., Brown, C. H., Hur, K., et al. (2012). Suicidal thoughts and behaviors with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Archives of General Psychiatry, 69(6), 580–587.
Grunebaum, M., Ellis, S., Duan, N., et al. (2012). Pilot randomized clinical trial of an SSRI vs Bupropion: Effects on suicidal behavior, ideation and mood in major depression. Neuropsychopharmacology, 37, 697–706.
Hammad, T. A., Laughren, T., & Racoosin, J. (2006). Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry, 63, 332–339.
Hawton, K., Bergen, H., Simkin, S., et al. (2010). Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. British Journal of Psychiatry, 196, 354–358.
Jenner, P. N. (1992). Paroxetine: an overview of dosage, tolerability and safety. International Clinical Psychopharmacology, 6(4), 69–80.
Kasper, S., Fuger, J., & Moller, J. H. (1992). Comparative efficacy of antidepressants. Drugs, 43, 11–23.
Kasper, S., Montgomery, S. A., Möller, H. J., et al. (2010). Longitudinal analysis of the suicidal behavior risk in short-term, placebo-controlled studies of mirtazapine in major depressive disorder. World Journal of Biological Psychiatry, 11(1), 36–44.
Khan, A., Khan, S., Kolts, R., et al. (2003). Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. American Journal of Psychiatry, 160, 790–792.
Laje, G., Paddock, S., Manji, H., et al. (2007). Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. American Journal of Psychiatry, 164, 1530–1538.
Llorca, P. M., Brousse, G., & Schwan, R. (2005). Escitalopram for treatment of major depressive disorder in adults. Encephale, 31, 490–501.
Nelson, J. C., Delucchi, K., & Schneider, L. (2007). Suicidal thinking and behavior during treatment with sertraline in late-life depression. American Journal of Geriatric Psychiatry, 15(7), 573–580.
Nemeroff, C. B., Kalali, A., & Keller, M. (2007). Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Archives of General Psychiatry, 64(4), 466–472.
Nemeroff, C. B., Entsvah, R., & Benattia, I., et al. (2008). Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biological Psychiatry, 63(4), 424–434.
Schneeweiss, S., Patrick, A. R., Solomon, D. H., et al. (2010). Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years’ data. Archives of General Psychiatry, 67(5), 497–506.
Teicher, M. H., Glod, C., & Cole, J. O. (1990). Emergence of intense suicidal preoccupation during fluoxetine treatment. American Journal of Psychiatry, 147(2), 207–210.
Thase, M. E. (1998). Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. Journal of Clinical Psychiatry, 59, 502–508.
Tiihonen, J., Lonnqvist, J., Haukka, J., et al. (2006). Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Archives of General Psychiatry, 63, 1358–1367.
US Food and Drug Administration: Clinical Review: relationship between antidepressant drugs and suicidality in adults. Available from: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006–4272b1–01-FDA.pdf)
Valenstein, M., Kim, H. M., Ganoczy, D., et al. (2012). Antidepressant agents and suicide death among US Department of Veterans Affairs patients in depression treatment. Journal of Clinical Psychopharmacology, 32(2), 346–353.
Vanderburg, D. G., Batzer, E., Fogel, I., et al (2009). A pooled analysis of suicidality in double-blind, placebo-controlled studies of sertraline in adults. Journal of Clinical Psychiatry, 70(5), 674–683.
Vey, E. L., & Kovelman, I. (2010). Adverse events, toxicology and post-mortem data on duloxetine: case reports and literature survey. Journal of Forensic and Legal Medicine, 17(4), 175–185.
von Knorring, A. L., Olsson, G. I., Thomsen, P. H., et al. (2006). A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. Journal of Clinical Psychopharmacology, 26(3), 311–315.